Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity

被引：0

作者：

Pyun, Jung-Min ^{[1
]}

Park, Young Ho ^{[2
,3
]}

Youn, Young Chul ^{[4
]}

Kang, Min Ju ^{[5
]}

Shim, Kyu Hwan ^{[6
]}

Jang, Jae-Won ^{[7
]}

You, Jihwan ^{[1
]}

Nho, Kwangsik ^{[8
,9
,10
]}

Kim, SangYun ^{[2
,3
]}

机构：

[1] Soonchunhyang Univ, Seoul Hosp, Dept Neurol, Coll Med, 59 Daesagwan Ro, Seoul 04401, South Korea

[2] Seoul Natl Univ, Bundang Hosp, Dept Neurol, 82 Gumi Ro 173 Beon Gil, Seongnam Si 13620, Gyeonggi Do, South Korea

[3] Seoul Natl Univ, Coll Med, 82,Gumi Ro 173 Beon Gil, Seongnam Si 13620, Gyeonggi Do, South Korea

[4] Chung Ang Univ Hosp, Dept Neurol, 102 Heukseok Ro, Seoul 06973, South Korea

[5] Vet Hlth Serv Med Ctr, Dept Neurol, 53 Jinhwangdo Ro 61 Gil, Seoul 05368, South Korea

[6] Gachon Univ, Dept Bionano Technol, 1342 Seongnamdaero, Seongnam Si 13120, Gyeonggi Do, South Korea

[7] Kangwon Natl Univ, Kangwon Natl Univ Hosp, Coll Med, Dept Neurol, 156 Baengnyeong Ro, Chuncheon Si 24289, Gangwon Do, South Korea

[8] Indiana Univ Sch Med, Dept Radiol & Imaging Sci, 355 W 16th,GH 4101, Indianapolis, IN 46202 USA

[9] Indiana Univ Sch Med, Indiana Alzheimer Dis Ctr, 355 W 16th,GH 4101, Indianapolis, IN 46202 USA

[10] Indiana Univ Sch Med, Ctr Computat Biol & Bioinformat, 410 W 10th,Hlth Informat & Translat Sci Bldg, Indianapolis, IN 46202 USA

来源：

TRANSLATIONAL PSYCHIATRY | 2024年 / 14卷 / 01期

基金：

美国国家卫生研究院; 加拿大健康研究院;

关键词：

ALZHEIMERS-DISEASE; COMPOSITE SCORE; DEMENTIA;

D O I：

10.1038/s41398-024-02766-6

中图分类号：

R749 [精神病学];

学科分类号：

100205 ;

摘要：

Various plasma biomarkers for amyloid-beta (A beta) have shown high predictability of amyloid PET positivity. However, the characteristics of discordance between amyloid PET and plasma A beta 42/40 positivity are poorly understood. Thorough interpretation of discordant cases is vital as A beta plasma biomarker is imminent to integrate into clinical guidelines. We aimed to determine the characteristics of discordant groups between amyloid PET and plasma A beta 42/40 positivity, and inter-assays variability depending on plasma assays. We compared tau burden measured by PET, brain volume assessed by MRI, cross-sectional cognitive function, longitudinal cognitive decline and polygenic risk score (PRS) between PET/plasma groups (PET-/plasma-, PET-/plasma+, PET+/plasma-, PET+/plasma+) using Alzheimer's Disease Neuroimaging Initiative database. Additionally, we investigated inter-assays variability between immunoprecipitation followed by mass spectrometry method developed at Washington University (IP-MS-WashU) and Elecsys immunoassay from Roche (IA-Elc). PET+/plasma+ was significantly associated with higher tau burden assessed by PET in entorhinal, Braak III/IV, and Braak V/VI regions, and with decreased volume of hippocampal and precuneus regions compared to PET-/plasma-. PET+/plasma+ showed poor performances in global cognition, memory, executive and daily-life function, and rapid cognitive decline. PET+/plasma+ was related to high PRS. The PET-/plasma+ showed intermediate changes between PET-/plasma- and PET+/plasma+ in terms of tau burden, hippocampal and precuneus volume, cross-sectional and longitudinal cognition, and PRS. PET+/plasma- represented heterogeneous characteristics with most prominent variability depending on plasma assays. Moreover, IP-MS-WashU showed more linear association between amyloid PET standardized uptake value ratio and plasma A beta 42/40 than IA-Elc. IA-Elc showed more plasma A beta 42/40 positivity in the amyloid PET-negative stage than IP-MS-WashU. Characteristics of PET-/plasma+ support plasma biomarkers as early biomarker of amyloidopathy prior to amyloid PET. Various plasma biomarker assays might be applied distinctively to detect different target subjects or disease stages.

引用

页数：9

共 22 条

[1] A global reference for human genetic variation [J].

Altshuler, David M. ;

Durbin, Richard M. ;

Abecasis, Goncalo R. ;

Bentley, David R. ;

Chakravarti, Aravinda ;

Clark, Andrew G. ;

Donnelly, Peter ;

Eichler, Evan E. ;

Flicek, Paul ;

Gabriel, Stacey B. ;

Gibbs, Richard A. ;

Green, Eric D. ;

Hurles, Matthew E. ;

Knoppers, Bartha M. ;

Korbel, Jan O. ;

Lander, Eric S. ;

Lee, Charles ;

Lehrach, Hans ;

Mardis, Elaine R. ;

Marth, Gabor T. ;

McVean, Gil A. ;

Nickerson, Deborah A. ;

Wang, Jun ;

Wilson, Richard K. ;

Boerwinkle, Eric ;

Doddapaneni, Harsha ;

Han, Yi ;

Korchina, Viktoriya ;

Kovar, Christie ;

Lee, Sandra ;

Muzny, Donna ;

Reid, Jeffrey G. ;

Zhu, Yiming ;

Chang, Yuqi ;

Feng, Qiang ;

Fang, Xiaodong ;

Guo, Xiaosen ;

Jian, Min ;

Jiang, Hui ;

Jin, Xin ;

Lan, Tianming ;

Li, Guoqing ;

Li, Jingxiang ;

Li, Yingrui ;

Liu, Shengmao ;

Liu, Xiao ;

Lu, Yao ;

Ma, Xuedi ;

Tang, Meifang ;

Wang, Bo .

NATURE, 2015, 526 (7571) :68-+

[2] NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].

BRAAK, H ;

BRAAK, E .

ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259

[3] Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI) [J].

Crane, Paul K. ;

Carle, Adam ;

Gibbons, Laura E. ;

Insel, Philip ;

Mackin, R. Scott ;

Gross, Alden ;

Jones, Richard N. ;

Mukherjee, Shubhabrata ;

Curtis, S. McKay ;

Harvey, Danielle ;

Weiner, Michael ;

Mungas, Dan .

BRAIN IMAGING AND BEHAVIOR, 2012, 6 (04) :502-516

[4] Discordant amyloid-β PET and CSF biomarkers and its clinical consequences [J].

de Wilde, Arno ;

Reimand, Juhan ;

Teunissen, Charlotte E. ;

Zwan, Marissa ;

Windhorst, Albert D. ;

Boellaard, Ronald ;

van der Flier, Wiesje M. ;

Scheltens, Philip ;

van Berckel, Bart N. M. ;

Bouwman, Femke ;

Ossenkoppele, Rik .

ALZHEIMERS RESEARCH & THERAPY, 2019, 11 (01)

[5] Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging [J].

Doecke, James D. ;

Ward, Larry ;

Burnham, Samantha C. ;

Villemagne, Victor L. ;

Li, Qiao-Xin ;

Collins, Steven ;

Fowler, Christopher J. ;

Manuilova, Ekaterina ;

Widmann, Monika ;

Rainey-Smith, Stephanie R. ;

Martins, Ralph N. ;

Masters, Colin L. .

ALZHEIMERS RESEARCH & THERAPY, 2020, 12 (01)

[6] PRSice: Polygenic Risk Score software [J].

Euesden, Jack ;

Lewis, Cathryn M. ;

O'Reilly, Paul F. .

BIOINFORMATICS, 2015, 31 (09) :1466-1468

[7] MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].

FOLSTEIN, MF ;

FOLSTEIN, SE ;

MCHUGH, PR .

JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198

[8] A composite score for executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment [J].

Gibbons, Laura E. ;

Carle, Adam C. ;

Mackin, R. Scott ;

Harvey, Danielle ;

Mukherjee, Shubhabrata ;

Insel, Philip ;

Curtis, S. McKay ;

Mungas, Dan ;

Crane, Paul K. .

BRAIN IMAGING AND BEHAVIOR, 2012, 6 (04) :517-527

[9] Update on the Magnetic Resonance Imaging core of the Alzheimer's Disease Neuroimaging Initiative [J].

Jack, Clifford R., Jr. ;

Bernstein, Matt A. ;

Borowski, Bret J. ;

Gunter, Jeffrey L. ;

Fox, Nick C. ;

Thompson, Paul M. ;

Schuff, Norbert ;

Krueger, Gunnar ;

Killiany, Ronald J. ;

DeCarli, Charles S. ;

Dale, Anders M. ;

Carmichael, Owen W. ;

Tosun, Duygu ;

Weiner, Michael W. .

ALZHEIMERS & DEMENTIA, 2010, 6 (03) :212-220

[10] Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease [J].

Janelidze, Shorena ;

Teunissen, Charlotte E. ;

Zetterberg, Henrik ;

Allue, Jose Antonio ;

Sarasa, Leticia ;

Eichenlaub, Udo ;

Bittner, Tobias ;

Ovod, Vitaliy ;

Verberk, Inge M. W. ;

Toba, Kenji ;

Nakamura, Akinori ;

Bateman, Randall J. ;

Blennow, Kaj ;

Hansson, Oskar .

JAMA NEUROLOGY, 2021, 78 (11) :1375-1382

← 1 2 3 →